Novocardia, a value-based cardiovascular disease care delivery platform, today announced it has been named a “Rising Disruptor” by Bernstein, a global equity research firm, in its 2021 report on the most disruptive private health care services companies in the United States.
| NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Novocardia, a value-based cardiovascular disease care delivery platform, today announced it has been named a “Rising Disruptor” by Bernstein, a global equity research firm, in its 2021 report on the most disruptive private health care services companies in the United States. Novocardia’s significant potential to change cardiovascular disease care makes them stand out as a Rising Disruptor. The “2021 Bernstein Disruptors 25" report recognizes private health care companies that are innovative leaders positioned to transform the efficiency, outcomes, or delivery of care in the United States. Bernstein analysts selected companies leading major disruption trends, including value-based care, digital-first health care, reinventing care delivery, and whole person health/health equity. The report ranked this year’s top 25 Disruptors and named Rising Disruptors, which are earlier-stage companies that represent important disruption themes and have the potential for significant impact on how health care is delivered. Novocardia was selected as one of six Rising Disruptors. “Novocardia is thrilled to be recognized by Bernstein as a Rising Disruptor in U.S. health care services for 2021,” said Daniel Blumenthal, MD, MBA, Chief Executive Officer of Novocardia. “We are truly passionate about improving the delivery of cardiovascular care in this country, and we believe empowering cardiologists through value-based care, and fee-for-value reimbursement models is the vehicle through which we make that happen. Novocardia is proud to be at the forefront of this pivotal transformation in cardiovascular care.” Bernstein analysts identified the shift to value-based care as the largest disruption to the U.S. health care system. According to the report, value-based care has the potential to reduce health care costs by $1 trillion. The current value-based care sector is estimated to grow from $250 billion today to nearly $900 billion in 2030 and increase total medical spending from 2% in 2020 to 12% by 2030.* “Novocardia’s significant potential to change cardiovascular disease care through a value-based care delivery platform emphasizing proactive and prevention-focused care made the company stand out as a Rising Disruptor,” said Lance Wilkes, Bernstein’s Senior Analyst covering U.S. Health Care Services. “With increasing demands for cost-effectiveness, convenience, and improved health outcomes, the pace of disruption in the health care industry is continuing to accelerate, and we look forward to seeing how Novocardia grows in the new year.” * Bernstein, September 2021, “The 2021 Bernstein Disruptors 25,” www.bernstein.com ABOUT NOVOCARDIA™ ABOUT BERNSTEIN
SOURCE Novocardia |
View original content:
